Volume 68, Issue 6, Pages e129-e131 (December 2015)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

European Urology Focus

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 65, Issue 5, Pages (May 2014)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 66, Issue 3, Pages (September 2014)

Volume 60, Issue 4, Pages (October 2011)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 59, Issue 3, Pages e7-e8 (March 2011)

Volume 70, Issue 1, Pages e27-e28 (July 2016)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 73, Issue 5, Pages (May 2018)

Volume 71, Issue 6, Pages (June 2017)

Volume 66, Issue 6, Pages (December 2014)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

European Urology Oncology

Volume 52, Issue 6, Pages (December 2007)

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 68, Issue 6, Pages e129-e131 (December 2015) Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration- resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147–53 Kevin Lu European Urology Volume 68, Issue 6, Pages e129-e131 (December 2015) DOI: 10.1016/j.eururo.2015.08.017 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 (A) Hypothetical clinical outcome of metastatic castration-resistant prostate cancer evaluated on the basis of Response Evaluation Criteria in Solid Tumors (RECIST). (B) Hypothetically estimated progression-free survival [4,5] of patients receiving sequential therapy. ABI=abiraterone; CBZ=cabazitaxel; DOC=docetaxel; ENZ=enzalutamide; ePFS=estimated progression-free survival; L=line of therapy; PSA=prostate-specific antigen; SIP=sipuleucel-T. European Urology 2015 68, e129-e131DOI: (10.1016/j.eururo.2015.08.017) Copyright © 2015 European Association of Urology Terms and Conditions